Diabetes startup Omada Health finally went public after 14 years. Here's who made bank.
Omada Health just became the second digital health company to IPO this year.
The chronic care company saw its shares jump Friday morning by over 38% above its initial price.
Here's what Omada's major investors' stakes are worth after the public market debut.
Omada Health just went public at a $1.1 billion valuation — 14 years after its founding.
It's the second digital health IPO of the year, following physical therapy company Hinge Health, which went public on May 21. The two IPOs come after a multiyear drought for healthcare public market debuts.
And so far, Omada's IPO hasn't disappointed. While the chronic care company priced its initial shares at $19, its stock opened at $23 a share and jumped as high as $28.40 Friday morning, nearly a 50% increase.
Omada Health launched in 2011 to provide virtual care for prediabetes, making its name in the years following for diabetes management.
In recent years, its business has surged in new areas beyond diabetes care. Omada's weight care business has boomed as more patients taking GLP-1 drugs like Ozempic for weight loss seek companion care. The San Francisco-based company says most of its new employer and health plan clients approach Omada initially, interested in its metabolic health track.
Omada's initial valuation of $1.1 billion is roughly where it was privately valued. Omada's last private fundraise, a $192 million Series E round announced in February 2022, put Omada's valuation over $1 billion.
It's perhaps the best outcome Omada's investors could've hoped for, given that many digital health startups now looking to IPO last raised at huge valuations during VC's ZIRP period. Those valuations could be difficult to realize in today's market. Hinge Health, for example, went public at a $2.6 billion valuation after being valued in its 2021 fundraise at $6.2 billion.
We don't know what Omada Health's investors paid for their shares, so we can't calculate their profit. However, since Omada's shares opened on the stock market at $23, we used that price to determine the worth of its investors' stakes. None of Omada's major investors sold any shares in its IPO.
Here's what the stakes of Omada Health's major investors and executives are worth after its IPO.
Revelation Partners is a healthcare-focused investment firm that says it provides flexible capital to companies, especially to give liquidity to startups.
The firm first invested in Omada in September 2019, according to its website. Revelation Partners told Business Insider in an email that the firm invested in Omada through a series of secondary transactions. Omada hasn't mentioned Revelation Partners in previous press releases about its fundraises.
Revelation Partners owns about 5.2 million shares, or 9.3% of the company. At the $23 market debut price, the firm's stake is worth about $120 million.
US Venture Partners, an investor: $108.5 million
San Francisco-based US Venture Partners makes early-stage investments across healthcare, software, consumer, and security. The firm says it's invested $4.5 billion across 532 companies.
USVP led Omada Health's $4.7 million Series A fundraise in 2013. The firm contributed additional financing in Omada's Series B through D rounds.
General partner Dr. Jonathan Root has served on Omada's board of directors since the firm's 2013 investment.
USVP owns about 4.72 million shares, or 8.5% of Omada Health. At the $23 market debut price, the firm's stake is worth about $108.5 million.
Andreessen Horowitz, an investor: $106 million
VC giant Andreessen Horowitz, or A16z, first invested in Omada Health in 2015, when the firm led Omada's $23 million Series B.
The firm went on to invest in Omada's Series C and D fundraises, per PitchBook.
At the time of A16z's 2015 investment, former general partner Balaji Srinivasan joined Omada's board of directors. It's unclear when he stepped down from the board; he moved into a part-time role at A16z that same year.
A16z owns about 4.6 million shares, or 8.3% of the company. At the $23 market debut price, the firm's stake is worth about $106 million.
Fidelity Management and Research Company, an investor: $102 million
Fidelity Management and Research Company is the parent company of financial services giant Fidelity Investments. Fidelity has invested in a handful of healthcare startups over the years, leading rounds like now- public insurtech Oscar Health 's $400 million raise in 2016 and smart ring maker Oura 's $200 million Series D in December.
FMR led Omada's $192 million Series E fundraise in February 2022.
Fidelity owns about 4.4 million shares, or 8.0% of the company. At the $23 market debut price, the firm's stake is worth about $102 million.
Cigna Ventures, an investor: $79 million
Health insurance giant Cigna spun out a venture capital arm in 2018 to back healthcare companies. Omada Health was one of the firm's first bets.
Cigna began working with the diabetes company in 2015. Two years later, the insurer announced an investment in Omada, leading a $50 million round in 2017 that Cigna Ventures later called Omada's Series C-1 financing.
Cigna also expanded its partnership with Omada as part of its formal investment.
Cigna Ventures owns about 3.4 million shares, or 6.2% of the company. At the $23 market debut price, the firm's stake is worth about $79 million.
aMoon Fund, an investor: $62 million
Israeli VC firm aMoon fund invests in healthcare and life sciences companies from early to late stages. Founded in 2016, it has backed a number of biotech companies that later went public, including Sophia Genetics, which went public in 2021, and Amylyx Pharmaceuticals, which went public in 2022.
The firm first invested in Omada Health in its $192 million Series E round in 2022.
"The entire space of all these clusters of diseases that includes diabetes, hypertension, and obesity is going through a major revolution right now," aMoon Fund managing partner Tomer Berkowitz told BI. "The solution in the end will not just be based on drugs, but it'll be a combination of drugs and behavioral change. I think Omada plays a significant role in that."
aMoon owns about 2.7 million shares, or 4.9% of the company. At the $23 market debut price, the firm's stake is worth about $62 million.
Norwest Venture Partners, an investor: $58 million
San Francisco-based Norwest Venture Partners invests in early- to late-stage startups. It's backed more than 700 companies and manages over $15.5 billion in assets, per the firm. Its healthcare portfolio also includes hospital operations AI company Qventus, which raised $105 million in January led by private equity firm KKR, and behavioral health site Talkspace, which went public in a 2021 SPAC deal.
The firm led Omada's $48 million Series C round in 2015 and put additional funding into Omada's Series C-1 and D rounds.
Norwest owns about 2.5 million shares, or 4.5% of the company. At the $23 market debut price, the firm's stake is worth about $58 million.
Sean Duffy, CEO: $46 million
Sean Duffy cofounded Omada Health alongside Adrian James, Omada's former president, and Andrew DiMichele, former chief technology officer, in 2011. The startup sought to use technology to deliver care for chronic conditions, initially focusing on prediabetes, to patients in between visits with their primary care providers.
Duffy and James spun Omada out of the design and consulting firm IDEO, where they'd begun researching the challenges in prediabetes and metabolic disease care. For Duffy, the IDEO gig had begun as an internship while he was getting dual MD-MBA degrees at Harvard. Instead of returning to complete his studies, he turned his focus to the idea that would become Omada.
Before Omada, Duffy had created the interactive Microsoft Excel training tool Excel Everest, written about healthcare innovation for the medtech blog Medgadget, and worked in people analytics at Google.
Duffy owns about 2 million shares, or 3.5% of Omada Health. That number includes about 860,000 shares of common stock and 1.15 million stock options exercisable by May 30, according to Omada's S-1 filing.
At the $23 market debut price, his stake is worth about $46 million.
Wei-Li Shao, president: $13 million
Wei-Li Shao has served as Omada's president since 2021. He first joined the company in 2021 as its chief commercial officer.
Before Omada, Li spent a combined 17 years at Eli Lilly managing a number of the pharma giant's businesses and brands, including its Alzheimer's disease, diabetes, and neurosciences businesses.
Shao owns about 579,095 stock options exercisable by May 30, representing 1.0% of the company. He does not own any common stock.
At the $23 market debut price, his stake is worth about $13 million.
Steve Cook, CFO: $7.9 million
Steve Cook joined Omada Health as its chief financial officer in 2021. He'd previously led strategic finance efforts at primary care chain One Medical through its 2020 IPO. Before that, he spent six years in finance and strategy at Salesforce.
Cook owns about 340,000 stock options exercisable by May 30, giving him less than 1% ownership. He does not own any shares of common stock.
At the $23 market debut price, his stake is worth about $7.9 million.
Trevor Fetter, board member: $5.3 million
Trevor Fetter has served on Omada's board of directors since March 2021. He's a senior lecturer at Harvard University and the lead independent director of insurance business The Hartford.
Fetter is best known as the former chairman and CEO of health system giant Tenet Healthcare, a position he held for 15 years.
Fetter also holds advisory positions at multiple other private and public companies, sitting on the board of directors at healthtech startup Biofourmis and serving as a member of the advisory board of private equity firm TowerBrook Capital Partners.
Fetter owns about 231,000 shares, or less than 1% of the company. That number includes about 111,000 shares of common stock and 120,000 stock options exercisable by May 30.
At the $23 market debut price, his stake is worth about $5.3 million.
Jeryl Hilleman, chair of the board of directors: $4.8 million
Jeryl Hilleman has spent the majority of her career as a serial CFO, holding the lead finance role at five different companies across industries, including software, biotech, and medtech. All five companies were ultimately acquired.
Today, Hilleman is the chair of Omada's board of directors, a position she's held since 2019. She also serves on the boards of cancer therapeutics maker Novocure, which completed its IPO in February, as well as public medtech company Si-Bone and public vaccine maker HilleVax.
Hilleman owns about 210,000 stock options exercisable by May 30, which gives her less than 1% ownership of Omada. She does not own any common stock.
At the $23 market debut price, her stake is worth about $4.8 million.
Dr. Sachin Jain, board member: $604,000
Dr. Sachin Jain is the president and CEO of Medicare Advantage provider SCAN Health Plan. He joined Omada's board of directors in August.
Jain is also a professor of medicine at Stanford and a practicing academic hospitalist at the US Department of Veterans Affairs. Previously, he was a senior advisor to the administrator of the Centers for Medicare and Medicaid Services, the president and CEO of CareMore Health and Aspire Health, and the chief medical information and innovation officer at Merck.
Jain owns about 26,000 stock options exercisable by May 30, representing less than 1% of the company. He does not own any common stock.
At the $23 market debut price, his stake is worth about $604,000.
Julie Klapstein, board member: $527,000
Omada Health added Julie Klapstein to its board of directors in August. Klapstein was the founding CEO of Availity, one of the largest health information networks in the country. She spent nearly 11 years at Availity after its 2001 founding.
Since Availity, she's served as a board member at nearly two dozen public and private companies, including healthcare companies like value-based primary care chain Oak Street Health and investment firms like PE firm Riverside Partners. She's also been an advisor to Andreessen Horowitz, most recently serving as a partner advisor from 2023 through April, per her LinkedIn.
Klapstein owns about 23,000 stock options exercisable by May 30, representing less than 1% of the company. She does not own any common stock.
At the $23 market debut price, her stake is worth about $527,000.
Adam Stavisky, board member: $527,000
Omada added Adam Stavisky to its board of directors in August, alongside Klapstein and Jain.
He most recently spent six years as the senior vice president of US benefits at Walmart. Before that, he spent 13 years at Fidelity, leaving as its head of benefits consulting. In addition to his role at Omada, he's a member of the board of advisors at marketing agency StrawberryFrog.
Stavisky owns about 23,000 stock options exercisable by May 30, representing less than 1% of Omada Health. He does not own any common stock.
At the $23 market debut price, his stake is worth about $527,000.
Dr. Anne Beal, board member: $380,000
Omada added Dr. Anne Beal to its board of directors in October. Beal is the founder of AbsoluteJOI Skincare, a science-based clean beauty company. She's also a board member at pharma giant GSK and life sciences company Prolacta Biosciences.
She previously served as the chief patient officer at biopharma behemoth Sanofi.
Beal owns about 17,000 stock options exercisable by May 30, representing less than 1% of Omada Health. She does not own any common stock.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
Dairy is so back. It's now a high-protein, gut-healthy superfood shoppers love.
Want to snack on something that's high in protein, gut-friendly, minimally processed, and tastes good? Hit the dairy aisle. After years of being outshone and relegated to second best by shiny, new plant-based alternatives like oat milk and cashew cream, dairy is not only in demand, it's having a glow-up. Products like mint chocolate cookie probiotic ice cream and pistachio-flavored kefir — some of which come wrapped in whimsical, retro-style packaging — are hitting the market as dairy finds itself at the center of the Venn diagram of health, food, and cultural trends. "I really have not seen this type of dairy innovation in past years," Jessica Rubino of New Hope Network, an organic-focused consultancy firm that tracks US food and drink industry trends, told Business Insider. According to the organization's insights, the organic dairy sector grew by 9.8% in 2024, up from 5.6% the previous year — far higher than the one or two percent a year increase seen since around 2015. "That type of increase in growth is pretty significant," Rubino said. Dairy aligns with health trends With 82% of US consumers considering wellness a top or important priority in their everyday lives, according to 2024 trend data from McKinsey, food and drink can't just taste good, it needs to provide health benefits too. A large part of dairy's appeal right now is that it's high in protein and minimally processed. Whether you want to eat enough protein to build muscle, you use a GLP-1 and need more protein to maintain muscle mass or are a member of the manosphere following the carnivore diet, we've gone protein-crazy in recent years. The global protein market is estimated to reach over $47.4 billion by 2032, up from $26 billion in 2021, according to Statista. Protein-enhanced products, such as sodas, waters, powders, and bars, have taken over grocery store aisles. Fairlife, the industry leader in ultra-filtered milk, which contains 50% more protein than regular milk, has seen dollar sales rise by 31% in the past 12 months, according to data from market research agency Circana. The milk is filtered to separate its components (water, lactose, protein, fat, and vitamins and minerals) and reformulated. Lactose and sugar are removed, and protein is concentrated. Melissa Altobelli, a dairy industry analyst at Circana, told BI that Fairlife, which has been around since 2012, has exploded in popularity recently because its product chimes with current trends. "It's not that the effort wasn't made in the past. It's just more appealing to consumers currently," she said, adding: "Protein is in everything at this point, and that's what consumers are looking for." Rubino also sees gut health as a particularly big draw for dairy, as people seek out functional foods to "optimize" their health and live longer. "You can get high dosages of probiotics through these food products," she said. The ultra-processed foods backlash is good news for dairy As ultra-processed foods take over from carbs as the demon of the dietary world, shoppers are losing their appetite for them. Typically long-lasting and designed to be irresistible and easy to eat, these foods contain ingredients you wouldn't find in a regular kitchen, such as gums, emulsifiers, and colors. Mounting research links ultra-processed foods to a host of health conditions — from type 2 diabetes to depression and poor gut health. As public awareness of ultra-processed foods has grown, people have become more wary of alt milks, which typically contain additives, Amy Bentley, a professor of food studies at NYU who specializes in the American diet, told BI. "Alt meat and alt milk don't want to be put in that category. They want to say, 'Hey, we're different.' But if you read those ingredient labels of some of those alt products, they are very, very ultra processed," she said. This has been dairy's gain: "The pendulum has swung back," Andrea Hernández, the author of the food trends newsletter Snaxshot, told BI. "Milk was the original functional drink," Hernández said, "and it's become culturally cool again." "Consumers are still looking for simple ingredients and naturalness," Altobelli said. And traditional dairy products, like unflavored yogurts and cottage cheese, as well as more innovative ones like Fairlife, fit the bill. The cult status of raw dairy in a MAHA world Dairy products, including raw milk, have become part of a cultural conversation in the past year or so. Fans of raw milk say it contains more beneficial microbes than pasteurized milk and can protect against allergies and asthma. Food scientists, however, argue that the ostensible benefits of raw milk are outweighed on a population level by the risk of catching bird flu or being poisoned by E. coli. Raw milk, along with beef tallow and butter, has also become synonymous with the "make America healthy again," or MAHA, movement. Its spearhead, Robert F. Kennedy Jr, the US Health Secretary, said in June 2024 that he only drinks raw milk and, before he was appointed, criticized what he called the FDA's "aggressive suppression" of raw milk, which he said on X in October 2024 "advances human health." In late May, he took shots of the stuff in the White House on a podcast. Federal law prohibits the sale of raw milk across state lines, but individual state laws, not the FDA, dictate whether it can be sold within that state. Raw milk enthusiasts include people across the political and cultural spectrum. Republican congresswoman Marjorie Taylor Greene posted "Raw Milk does a body good" on X in October 2024. Gwyneth Paltrow, an early adopter of wellness culture, said she adds raw milk creamer to her coffee every morning. And "tradwife" influencer and dairy farmer Hannah Neeleman, who posts as "Ballerina Farm" online, was featured milking one of her cows on the cover of the conservative women's magazine Evie in November, emblazoned with the words " The New American Dream." Hernández said there is a "romanticization of a dairy farm or a farmer's life." "It's become trendy to be able to say, 'Oh, I got this $20 raw milk jug at Erewhon,'" the Los Angeles-based health food store known for its $20 smoothies, she said. The next era for dairy: exotic flavors with health benefits People may want their meals to be nutritious, but that doesn't mean they're willing to compromise on taste. On top of wellness, consumers, and Gen Z in particular, are looking for "unusual flavors as they seek new and unique experiences," according to branding consultancy and market research agency VML's Future 100: 2025 trends report. One in four of us want "interesting and exotic global flavor combinations," the report said. If the offerings at Natural Products Expo West, a prolific trade show for organic, sustainable food and beverage products, which took place in California in March, are any indication, brands are meeting the moment. Attendees could try ashwagandha -infused or Aleppo chile-flavored ghee, pineapple cottage cheese, and reduced-sugar chai tea-flavored yogurt. Alec's, an organic ice cream brand that displayed at the trade show, launched their Culture Cup, a 4 fl oz cup of ice cream with added pre- and probiotics, in April with flavors including chocolate-covered strawberry and dark chocolate honeycomb. All Things Butter, a company founded by the British chef Thomas Straker in 2023, has also gained traction for its flavored butters. Current products include cinnamon bun butter, chocolate butter, and smoked paprika butter. Unlike traditional butter packaging, its butter sticks come in colorful foil adorned with anthropomorphic cartoon cows. It was the first "very yassified, very millennial looking" dairy brand Hernández noticed, but she's certain we'll see many more.
Business Insider
2 hours ago
- Business Insider
I landed a remote job for a European company, and now I'd find it hard to go back to a US-based company — I feel spoiled by the perks
This as-told-to essay is based on a transcribed conversation with 34-year-old Meghan Gezo, from Michigan. The following has been edited for length and clarity. In 2022, I left my job working remotely in people operations for a US company. Juggling my job and raising my one-year-old wasn't working. I wanted to take a break while I looked for another opportunity that would allow me to have better work-life boundaries. After a few months of job hunting, I started as a people experience manager at Storyblok, a fully remote content management company based in Austria. I'd never worked for a company based in Europe before. Living in the US, most jobs that pop up are US-based. People have come to expect more work-life balance in Europe, as the employment laws differ from the US. For me, there have been perks related to my life as a parent, my working hours, and my professional growth. I was immediately drawn to the benefits of working for a European company I've been working in remote jobs for tech companies since 2016. I'd previously worked in an office, but thought a remote job meant I could focus on higher-impact work than the office administration that usually fell to HR, as well as branch out beyond the manufacturing and automotive industry jobs in my area. It was easier to find a remote job in 2022 than in 2016. I found the listing for Storyblok on a job board. The people I spoke with were genuine and direct. In the first interview, they talked about time off norms and said the standard workweek is 38.5 hours. They seemed to emphasize work-life balance and gave me concrete examples of how it worked at the company. I was optimistic I could be successful in the role while staying involved in my daughter's life. In the US, the norm on paper is a 40-hour workweek, but in practice, people often work until they finish their tasks, especially in tech. I used to work, feed my daughter, put her to bed, and then work some more. It felt normal. At my current company, you focus on work when you're at work and then log off until the next day. There have definitely been times when I've had to work extra hours, but overall, I'd say that my work-life balance is better. In the US, it can often feel that your work is your identity. My European colleagues take pride in their work and are extremely hard workers, but their job is one facet of their identity. Working for a European company has pushed me in new ways I've gained experience working with people from other cultures. Learning about Austrian law has also pushed me to expand my HR knowledge beyond US employment law. One thing I've noticed about the company culture is that when people are on vacation, they're on vacation. Meanwhile, it's more the norm in the US to answer messages on vacation. I've not completely broken this habit, but it has felt more attainable for me to delete work communication apps from my phone when I'm away. I've felt very supported in my role as a parent at my European company The Austrian norm of " care leave," which isn't a norm in the US, is a great part of working for a European company. Because I have kids under a certain age, I get to use two paid weeks off a year for days when my kids are sick and I need to take them to a doctor or take care of them. Having this bucket to pull from is a huge weight off my shoulders as a parent. My previous employers had generous parental leave policies. However, at Storyblok, I got slightly more time — 16 weeks. I went on maternity leave at a previous company with my firstborn and again at my current job in 2023. During my most recent maternity leave, people in the company treated it very seriously. I got a lot of support from my manager and team to help plan for my leave and assign my tasks to others. During my first maternity leave for a previous company, I didn't mind answering a few questions as needed to support my team, but at Storyblok, no one asked me work-related questions while I was away. There are some downsides While my working hours suit my season of life, there are days when I wish I could start later at 9 a.m. However, I don't think I'd be as effective without overlap with my European colleagues. Right now, I work 6:30 a.m. to 2:30 p.m. ET. Sometimes, if I have a question I want to ask colleagues in Europe during my afternoons, I'll know that I won't be getting an answer until the next day because of the time zone difference. I've learned to work these expectations into my regular workflow. It does make me sad that I don't live near my colleagues. I've built strong relationships with these people, but they're an ocean away. I'd find it hard to go back to a US-based company Working for a European company didn't occur to me as an option before I interviewed for this job. Having worked here for over two years, I feel spoiled by the benefits and perks of European working culture, and it would be hard for me to go back to working for a US-based company.
Yahoo
3 hours ago
- Yahoo
Port of SF to demolish Alioto's for public plaza
(KRON) — The building that housed Alioto's Restaurant for more than 80 years on San Francisco's Fisherman's Wharf will be torn down for a new $10 million wharf renovation envisioned by the Port of San Francisco. Alioto's, which served seafood at the wharf since 1925, as the now-empty storefront still boasts, shuttered during the pandemic when the Alioto family decided not to renew its lease. The Port of San Francisco now looks to turn the rundown, three-story building into a bustling central plaza. The plaza project is the first part of a multi-year program, which aims to reconnect visitors to the inner lagoon, improve facilities for fishermen and add protections against earthquakes and sea level rise. Giant lizard seen wandering Santa Clara County park San Francisco Supervisor Danny Sauter told KRON4 that the wharf 'shapes people's impressions of San Francisco from around the world as they come to visit.' 'It's really important to put our best foot forward and that Fisherman's Wharf is safe and clean and beautiful,' Sauter said Holding a cellphone for navigation while driving is illegal, California court rules According To The Port of San Francisco, the Fisherman's Wharf attracted more than 10 million people in 2024, making it the most visited destination in the city. Watch the full report from KRON4's Stephanie Rothman in the video at the top of this story. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
